Market research
ALBPS.PA Biophytis SA
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 2.2
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0012816825
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 2.2
- Dividend yield
- Not available
- Beta
- 0.85
About
About Biophytis SA
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALBPS.PA discussion.
5 years, 4 months ago
Biophytis SA is currently in a long term downtrend where the price is trading 23.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 106.6% to $-5M since the same quarter in the previous year.
Based on the above factors, Biophytis SA gets an overall score of 1/5.